Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (5): 475-481.doi: 10.3969/j.issn.1000-6621.2021.05.012
• Original Articles • Previous Articles Next Articles
WU Tuo-ya*, SHI Jin, GUO Ji-dong, LIU Yuan-yuan, PANG Yu, LU Jie(), GAO Fei()
Received:
2020-12-31
Online:
2021-05-10
Published:
2021-04-30
Contact:
LU Jie,GAO Fei
E-mail:lujiebch@163.com;gaofeiwho@163.com
WU Tuo-ya, SHI Jin, GUO Ji-dong, LIU Yuan-yuan, PANG Yu, LU Jie, GAO Fei. Mechanism of miR-21-3p modulating the survival of Mycobacterium tuberculosis in host macrophage[J]. Chinese Journal of Antituberculosis, 2021, 43(5): 475-481. doi: 10.3969/j.issn.1000-6621.2021.05.012
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.05.012
引物名称 | 引物序列 (5'~3') | 片段长度 (bp) |
---|---|---|
白细胞介素6(IL-6) | 149 | |
正向 | ACTCACCTCTTCAGAACGAATTG | |
反向 | CCATCTTTGGAAGGTTCAGGTTG | |
肿瘤坏死因子α (TNF-α) | 220 | |
正向 | CCTCTCTCTAATCAGCCCTCTG | |
反向 | GAGGACCTGGGAGTAGATGAG | |
三磷酸甘油醛脱氢酶(GAPDH) | 197 | |
正向 | GGAGCGAGATCCCTCCAAAAT | |
反向 | GGCTGTTGTCATACTTCTCATGG | |
核转录因子Y亚基β (NFYB) | 197 | |
正向 | ATGACAATGGATGGTGACAGTTC | |
反向 | CTAGCCACGTTTGCTATTGGA | |
kelch样家族成员3 (KLHL3) | 88 | |
正向 | ATACTGCTGAAATCGAGGTGACT | |
反向 | TTCTGCCGAACATCCATGAGC | |
父系表达基因3 (PEG3) | 124 | |
正向 | CACGCAGTTCCAAATCGGGA | |
反向 | CGCTGCTGGATCACTGACTC | |
周期蛋白依赖性激酶8(CDK-8) | 110 | |
正向 | GGGATCTCTATGTCGGCATGT | |
反向 | CACACCTTCCTATCAGCATGAG | |
泛素化因子E4B (UBE4B) | 79 | |
正向 | CTACCTCCCCAATAGGTGCAT | |
反向 | GGCGAGCTGCTGAGAGAAC | |
蛋白磷酸酶1催化亚基(PPP1CC) | 171 | |
正向 | TTTGCTGCGACTTTTTGAGTACG | |
反向 | GCACATTCATGGTTCCCTCTGA |
组别 | CDK-8 [M(Q1,Q3)] | KLHL3 [M(Q1,Q3)] | UBE4B [M(Q1,Q3)] | PPP1CC [M(Q1,Q3)] | NFYB [M(Q1,Q3)] | PEG3 [M(Q1,Q3)] |
---|---|---|---|---|---|---|
miR-21-3p模拟物对照组 | 1.025 (0.917,1.116) | 1.005 (0.973,1.053) | 0.960 (0.818,1.035) | 0.989 (0.979,1.007) | 1.000 (0.982,1.050) | 1.000 (0.923,1.155) |
miR-21-3p模拟物组 | 0.445 (0.434,0.467) | 1.760 (1.629,1.919) | 1.671 (1.591,1.758) | 1.097 (1.000,1.182) | 1.599 (1.464,1.753) | 1.564 (1.490,1.645) |
抑制剂对照组 | 0.966 (0.947,1.042) | 1.010 (0.973,1.161) | 0.990 (0.818,1.115) | 1.022 (1.007,1.089) | 1.003 (0.993,1.173) | 1.007 (0.990,1.010) |
抑制剂组 | 1.255 (1.185,1.466) | 0.367 (0.330,0.401) | 1.697 (1.591,1.729) | 0.938 (0.889,1.034) | 0.451 (0.376,0.463) | 1.160 (1.083,1.220) |
U值a | <0.001 | <0.001 | <0.001 | 7.000 | <0.001 | <0.001 |
P值a | 0.002 | 0.002 | 0.002 | 0.093 | 0.002 | 0.002 |
U值b | <0.001 | <0.001 | <0.001 | 8.000 | <0.001 | <0.001 |
P值b | 0.002 | 0.002 | 0.002 | 0.121 | 0.002 | 0.002 |
[1] |
Xu G, Wang J, Gao GF, et al. Insights into battles between Mycobacterium tuberculosis and macrophages. Protein Cell, 2014,5(10):728-736. doi: 10.1007/s13238-014-0077-5.
doi: 10.1007/s13238-014-0077-5 URL pmid: 24938416 |
[2] |
Zhai W, Wu F, Zhang Y, et al. The immune escape mechanisms of Mycobacterium tuberculosis. Int J Mol Sci, 2019,20(2):340. doi: 10.3390/ijms20020340.
doi: 10.3390/ijms20020340 URL |
[3] |
Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem, 2010,79:351-379. doi: 10.1146/annurev-biochem-060308-103103.
doi: 10.1146/annurev-biochem-060308-103103 URL pmid: 20533884 |
[4] |
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004,116(2):281-297. doi: 10.1016/s0092-8674(04)00045-5.
doi: 10.1016/s0092-8674(04)00045-5 URL pmid: 14744438 |
[5] |
Sonkoly E, Ståhle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol, 2008,18(2):131-140. doi: 10.1016/j.semcancer.2008.01.005.
doi: 10.1016/j.semcancer.2008.01.005 URL |
[6] |
Taganov KD, Boldin MP, Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity, 2007,26(2):133-137. doi: 10.1016/j.immuni.2007.02.005.
doi: 10.1016/j.immuni.2007.02.005 URL |
[7] |
Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature, 2005,435(7043):834-838. doi: 10.1038/nature03702.
doi: 10.1038/nature03702 URL pmid: 15944708 |
[8] |
Pink RC, Samuel P, Massa D, et al. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol, 2015,137(1):143-151. doi: 10.1016/j.ygyno.2014.12.042.
doi: 10.1016/j.ygyno.2014.12.042 URL pmid: 25579119 |
[9] |
Zhu Y, Tang H, Zhang L, et al. Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN. Cancer Manag Res, 2019,11:955-968. doi: 10.2147/CMAR.S183328.
doi: 10.2147/CMAR.S183328 URL pmid: 30774424 |
[10] |
Lo TF, Tsai WC, Chen ST. MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth. PLoS One, 2013,8(9):e75628. doi: 10.1371/journal.pone.0075628.
doi: 10.1371/journal.pone.0075628 URL pmid: 24098708 |
[11] |
Ge X, Li W, Huang S, et al. Increased miR-21-3p in injured brain microvascular endothelial cells after traumatic brain injury aggravates blood-brain barrier damage by promoting cellular apoptosis and inflammation through targeting MAT2B. J Neurotrauma, 2019,36(8):1291-1305. doi: 10.1089/neu.2018.5728.
doi: 10.1089/neu.2018.5728 URL pmid: 29695199 |
[12] |
Wang T, Jiang L, Wei X, et al. MiR-21-3p aggravates injury in rats with acute hemorrhagic necrotizing pancreatitis by activating TRP signaling pathway. Biomed Pharmacother, 2018,107:1744-1753. doi: 10.1016/j.biopha.2018.08.164.
doi: 10.1016/j.biopha.2018.08.164 URL pmid: 30257393 |
[13] |
Xia B, Lu J, Wang R, et al. miR-21-3p regulates influenza a virus replication by targeting histone deacetylase-8. Front Cell Infect Microbiol, 2018,8:175. doi: 10.3389/fcimb.2018.00175.
doi: 10.3389/fcimb.2018.00175 URL pmid: 29888214 |
[14] |
Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer, 2006,6(4):259-269. doi: 10.1038/nrc1840.
doi: 10.1038/nrc1840 URL pmid: 16557279 |
[15] |
Ouimet M, Koster S, Sakowski E, et al. Mycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism. Nat Immunol, 2016,17(6):677-686. doi: 10.1038/ni.3434.
doi: 10.1038/ni.3434 URL pmid: 27089382 |
[16] |
Kim JK, Lee HM, Park KS, et al. MIR144* inhibits antimicrobial responses against Mycobacterium tuberculosis in human monocytes and macrophages by targeting the autophagy protein DRAM2. Autophagy, 2016,13(2):423-441. doi: 10.1080/15548627.2016.1241922.
doi: 10.1080/15548627.2016.1241922 URL pmid: 27764573 |
[17] |
Liu F, Chen J, Wang P, et al. MicroRNA-27a controls the intracellular survival of Mycobacterium tuberculosis by regulating calcium-associated autophagy. Nat Commun, 2018,9(1):4295. doi: 10.1038/s41467-018-06836-4.
doi: 10.1038/s41467-018-06836-4 URL pmid: 30327467 |
[18] |
Wu Y, Sun Q, Dai L. Immune regulation of miR-30 on the Mycobacterium tuberculosis-induced TLR/MyD88 signaling pathway in THP-1 cells. Exp Ther Med, 2017,14(4):3299-3303. doi: 10.3892/etm.2017.4872.
URL pmid: 28912881 |
[19] |
Chen Z, Wang T, Liu Z, et al. Inhibition of autophagy by miR-30A induced by Mycobacteria tuberculosis as a possible mechanism of immune escape in human macrophages. Jpn J Infect Dis, 2015,68(5):420-424. doi: 10.7883/yoken.JJID.2014.466.
URL pmid: 25866116 |
[20] |
Yang T, Ge B. miRNAs in immune responses to Mycobacterium tuberculosis infection. Cancer Lett, 2018,431:22-30. doi: 10.1016/j.canlet.2018.05.028.
doi: 10.1016/j.canlet.2018.05.028 URL pmid: 29803788 |
[21] |
Korla K, Arrigo P, Mitra CK. Promoters, toll like receptors and microRNAs: a strange association. Indian J Biochem Biophys, 2013,50(3):169-176.
URL pmid: 23898479 |
[22] |
Moresco EM, Lavine D, Beutler B. Toll-like receptors. Curr Biol, 2011,21(13):R488-R493. doi: 10.1016/j.cub.2011.05.039.
URL pmid: 21741580 |
[23] |
Saba R, Sorensen DL, Booth SA. MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front Immunol, 2014,5:578. doi: 10.3389/fimmu.2014.00578.
doi: 10.3389/fimmu.2014.00578 URL pmid: 25484882 |
[24] |
Li S, Yue Y, Xu W, et al. MicroRNA-146a represses mycobacteria-induced inflammatory response and facilitates bacterial replication via targeting IRAK-1 and TRAF-6. PLoS One, 2013,8(12):e81438. doi: 10.1371/journal.pone.0081438.
doi: 10.1371/journal.pone.0081438 URL pmid: 24358114 |
[25] |
Mahadik K, Prakhar P, Rajmani RS, et al. c-Abl-TWIST1 epigenetically dysregulate inflammatory responses during mycobacterial infection by co-regulating bone morphogenesis protein and miR27a. Front Immunol, 2018,9:85. doi: 10.3389/fimmu.2018.00085.
doi: 10.3389/fimmu.2018.00085 URL pmid: 29449840 |
[26] | Menzl I, Witalisz-Siepracka A, Sexl V. CDK8-novel therapeutic opportunities. Pharmaceuticals (Basel), 2019,12(2):92. doi: 10.3390/ph12020092. |
[27] |
Chen M, Liang J, Ji H, et al. CDK8/19 Mediator kinases potentiate induction of transcription by NFkappaB. Proc Natl Acad Sci U S A, 2017,114(38):10208-10213. doi: 10.1073/pnas.1710467114.
doi: 10.1073/pnas.1710467114 URL pmid: 28855340 |
[28] |
Fant CB, Taatjes DJ. Regulatory functions of the Mediator kinases CDK8 and CDK19. Transcription, 2018,10(2):76-90. doi: 10.1080/21541264.2018.1556915.
doi: 10.1080/21541264.2018.1556915 URL pmid: 30585107 |
[29] |
Yamamoto S, Hagihara T, Horiuchi Y, et al. Mediator cyclin-dependent kinases upregulate transcription of inflammatory genes in cooperation with NF-κB and C/EBPβ on stimulation of Toll-like receptor 9. Genes Cells, 2017,22(3):265-276. doi: 10.1111/gtc.12475.
URL pmid: 28151579 |
[1] | National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879. |
[2] | Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910. |
[3] | Xie Jingyi, Zou Ruifeng, Chen Yulan, Chen Yong, Liu Dongzhou, Hong Xiaoping. Analysis of clinical features and peripheral lymphocyte subsets of systemic lupus erythematosus patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 911-916. |
[4] | Cheng Xiao, Chen Zhe, Jiao Xuefeng, Yang Nan, Diao Sha, Ni Xiaofeng, Liu Zheng, He Siyi, Zeng Linan, Wan Chaomin, Kang Deying, Wu Bin, Ying Binwu, Zhang Hui, Zhao Rongsheng, Zhang Lingli. Efficacy and safety of recombinant Mycobacterium tuberculosis fusion proteins (EC) for the diagnosis of Mycobacterium tuberculosis infection: A system review [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 917-926. |
[5] | Wu Wenqi, Zhong Jianqiu, He Juan, Deng Guofang, Wang Qingwen. The research progress of the reactivation of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 954-959. |
[6] | Dong Xiaowei, Guo Huixin, Zhang Chenchen, Wang Jiawen, He Junlei, Li Guanhai, Li Jianwei, Wen Wenpei. Application value of two-step detection of Mycobacterium tuberculosis infection screening in schools [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 802-807. |
[7] | Li Yinhong, Liu Fanglin, Lu Zhenhui, Jiang Xin. Study on the mechanism of Oridonin against pathological damage of tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 849-854. |
[8] | XIA Hui, ZHENG Yang, SONG Yuan-yuan. Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645. |
[9] | LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653. |
[10] | DAI Xiao-wei, WANG Nen-han, CHEN Shuang-shuang, YANG Xin-yu, TIAN Li-li, CHEN Hong, ZHANG Hong-tai, LI Chuan-you. Assessing next-generation sequencing for Mycobacterium tuberculosis diagnosis in clinical sputum samples [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 669-679. |
[11] | JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping. Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726. |
[12] | HE Yi-jun, CAO Xue-fang, GAO Lei. Interpretation of the Procedure of tuberculin skin test-interferon-gamma release assay two-step testing [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 438-441. |
[13] | DAI Guang-ming, WANG fen, CAO Ting-ming, CHU Hong-qian, HUANG Hai-rong, SUN Zhao-gang. Study on efficiency of Mycobacterium tuberculosis detection by real-time quantitative PCR with different clinical sample types and the improvement by grinding specimen with glass beads [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 450-454. |
[14] | SUN Qing, LIAO Xin-lei, WANG Chen-qian, JIANG Guang-lu, DONG Ling-ling, WANG Fen, ZHAO Li-ping, HUANG Hai-rong, WANG Gui-rong. Characterization of rifampin resistance determining region mutations in tuberculosis patients with GeneXpert MTB/RIF positive RNA polymerase β subunit gene mutation [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 349-353. |
[15] | TIAN Li, ZHOU Wei, HUANG Xing, WU Xian-wei, ZHANG Hui-yong, LU Zhen-hui, ZHANG Shao-yan. Analysis of gene mutation characteristics of isoniazid-resistant Mycobacterium tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 354-361. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||